All In Biotech

Drug Trial Radar · NCT03638830

Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Randomized, Blind, Placebo-controlled Study to Evaluate Safety and Efficacy of Ftortiazinon in Combination With Maxipime®, in Comparison With Placebo in Combination With Maxipime®, in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 777 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

777

Actual

Start

Oct 17, 2018

Primary completion

Nov 23, 2022

Study completion Nov 23, 2022

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Acellena Contract Drug Research and Development
First posted
Aug 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is planned to evaluate the safety and efficacy of the drug Ftortiazinon in combination with the drug Maxipime® in comparison with placebo in combination with the drug Maxipime® in the treatment of hospitalized adult patients with complicated urinary tract infections caused by P. aeruginosa.

Conditions

  • Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
  • Pseudomonas Aeruginosa
  • Pseudomonas Infections
  • Urinary Tract Infections

Interventions

  • Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ MaxipimDrug

    Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)+placebo

  • Ftortiazinon (tablets 300 mg) full dose + MaxipimDrug

    Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)

  • placebo+MaxipimOther

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical cure and microbiological eradicationTime frame: through the whole study, an average of 90 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Baltic Medicine

    Saint Petersburg, Russia

  • Scientific and Research Center "Eco-Safety"

    Saint Petersburg, Russia

  • Vsevolozhsk Clinical Interdistrict Hospital

    Vsevolozhsk, Russia

  • Road Clinical Hospital of Open Joint Stock Company "Russian Railways

    Saint Petersburg, Sankt-Peterburg, Russia

  • St. Petersburg state budgetary institution of health care " City hospital № 26"

    Saint Petersburg, Sankt-Peterburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.